Aptevo Therapeutics Inc. reported a net loss of $6.23 per share for its fourth‑quarter 2025 results, beating the consensus estimate of a $8.10 loss per share.
The loss per share represents a 97.38% reduction from the prior‑year loss of $237.60 per share, correcting the earlier misstatement of a 23% improvement.
The improvement is largely attributable to disciplined cost management and a continued focus on advancing mipletamig, the company’s lead bispecific antibody for acute myeloid leukemia, which has shown encouraging remission rates and no cytokine release syndrome in frontline patients.
Management highlighted progress: "2025 was a year of meaningful progress across our clinical programs, pipeline strategy and capital position," said President and CEO Marvin White. "Most importantly, recently reported mipletamig data continue to demonstrate encouraging remission outcomes together with a favorable safety profile, including no cytokine release syndrome observed in frontline patients treated to date."
Despite the loss, Aptevo maintains a cash balance of $21.1 million as of September 30 2025 and has recently completed a capital raise in Q3 2025 and established an equity line in 2026 to support ongoing clinical development.
The company continues to invest in its pipeline, including trispecific candidates APVO451 and APVO452 for solid tumors, underscoring a broader strategy to diversify beyond AML.
The earnings beat signals that Aptevo’s cost controls are effective, but the company remains far from profitability, and investors will monitor future capital needs and milestone achievements.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.